highlight
selfassembl
nanoparticl
present
conserv
receptorbind
domain
nanoparticl
elicit
potent
neutral
antibodi
solubl
neutral
antibodi
predominantli
target
site
nanoparticl
elicit
potent
neutral
antibodi
mice
nonhuman
primat
summari
epsteinbarr
viru
ebv
repres
major
global
health
problem
though
associ
infecti
mononucleosi
cancer
annual
worldwid
vaccin
avail
major
target
immun
ebv
glycoprotein
mediat
attach
b
cell
complement
receptor
creat
selfassembl
nanoparticl
display
differ
domain
symmetr
array
focus
present
domain
nanoparticl
potent
neutral
antibodi
elicit
mice
nonhuman
primat
structur
design
nanoparticl
vaccin
increas
neutral
compar
solubl
target
function
conserv
site
vulner
improv
vaccineinduc
protect
mous
model
ration
approach
ebv
vaccin
design
elicit
potent
neutral
antibodi
respons
array
present
conserv
viral
entri
domain
strategi
appli
virus
correspond
jcohen
niaidnihgov
jic
garynabel
sanoficom
gjn
brief
structur
design
ebv
vaccin
candid
base
selfassembl
nanoparticl
elicit
potent
durabl
virusneutr
antibodi
target
receptorbind
site
viral
envelop
protein
site
vulner
serv
templat
develop
ebv
vaccin
provid
basi
immunofocus
ration
vaccin
design
introduct
epsteinbarr
viru
ebv
infect
associ
multipl
human
diseas
includ
infecti
mononucleosi
im
varieti
malign
burkitt
hodgkin
lymphoma
gastric
nasopharyng
carcinoma
among
neoplasm
observ
infect
lymphoprolif
disord
preval
sever
diseas
underscor
potenti
public
health
benefit
ebv
vaccin
despit
morbid
associ
ebv
prophylact
vaccin
though
viru
isol
identifi
half
centuri
ago
epstein
et
al
attempt
develop
vaccin
focus
viral
major
envelop
glycoprotein
repres
princip
target
neutral
antibodi
natur
infect
individu
hoffman
et
al
thorleylawson
geiling
thorleylawson
poodri
prototyp
vaccin
induc
protect
immun
ebvmedi
lymphoma
cottontop
tamarin
challeng
model
diseas
epstein
et
al
recent
reduc
infect
rhesu
macaqu
model
immun
challeng
perform
use
rhesu
macaqu
lymphocryptoviru
homolog
ebv
sashihara
et
al
select
candid
prophylact
ebv
vaccin
evalu
human
elliott
et
al
gu
et
al
moutschen
et
al
sokal
et
al
phase
ii
trial
ebv
prophylact
vaccin
use
recombin
solubl
adjuv
vaccin
demonstr
reduct
rate
im
ebvseroneg
vaccin
protect
acquisit
primari
infect
limit
enthusiasm
develop
ebv
infect
b
cell
engag
viral
primari
receptor
complement
receptor
fingeroth
et
al
altern
ogembo
et
al
heterotrimer
viral
glycoprotein
complex
bind
hla
class
ii
molecul
coreceptor
b
cell
heterodimer
ghgl
engag
integrin
primari
receptor
infect
epitheli
cell
connolli
et
al
huttfletch
tugizov
et
al
although
inhibit
viral
glycoprotein
antibodi
gene
disrupt
prevent
sever
impair
viral
infect
cell
degre
viru
neutral
vari
antibodi
specif
target
cell
type
murin
monoclon
antibodi
mab
potent
neutral
ebv
infect
b
cell
hoffman
et
al
predict
epitop
larg
overlap
infer
bind
site
suggest
mechan
neutral
mediat
antibodi
tanner
et
al
mab
also
block
interact
ogembo
et
al
indic
epitop
function
import
henc
attract
vaccin
target
prevent
viral
infect
b
cell
princip
target
cell
type
ebv
aim
elicit
potent
neutral
antibodi
epitop
immun
vaccin
design
base
ration
understand
structur
biolog
nanotechnolog
optim
present
recognit
site
vulner
display
monomer
antigen
surfac
selfassembl
nanoparticl
identifi
two
potenti
platform
ferritin
cho
et
al
encapsulin
sutter
et
al
ferritin
form
octahedr
cage
consist
subunit
encapsulin
form
icosahedron
made
ident
subunit
ferritin
engin
multipl
purpos
huard
et
al
inen
et
al
li
et
al
meldrum
et
al
among
innov
recent
develop
platform
mount
viral
trimer
glycoprotein
ferritin
axe
provid
basi
structurebas
nanoparticul
immunogen
comparison
ferritin
structur
reveal
certain
ferritin
includ
human
light
chain
wang
et
al
pdb
bullfrog
lower
subunit
trikha
et
al
pdb
contain
nh
termin
extens
present
ferritin
helicobact
pylori
cho
et
al
pdb
nh
termin
extens
make
nh
termin
residu
project
radial
nanoparticl
core
termini
evenli
space
surfac
due
rel
high
sequenc
homolog
bullfrog
human
ferritin
concern
use
either
vaccin
platform
could
induc
autoimmun
reaction
overal
architectur
ferritin
subunit
differ
speci
larg
similar
although
sequenc
h
pylori
hu
b
schemat
represent
fulllength
truncat
variant
nanoparticl
domain
ii
iii
color
code
dark
blue
sky
blue
pale
blue
respect
structur
undefin
region
transmembran
tm
cytoplasm
tail
ct
color
gray
white
respect
hexahistidin
tag
ferritin
encapsulin
color
black
red
green
respect
amino
acid
aa
posit
rel
fulllength
indic
bottom
see
also
figur
man
ferritin
divers
ident
human
light
heavi
chain
respect
avoid
potenti
vaccineinduc
autoimmun
therefor
fuse
amino
termin
extens
bullfrog
ferritin
h
pylori
ferritin
build
hybrid
antigenattach
site
distribut
evenli
surfac
figur
left
although
encapsulin
studi
scaffold
present
heterolog
protein
surfac
found
coohtermin
encapsulin
subunit
project
outward
particl
core
locat
proxim
symmetri
axi
figur
right
allow
us
creat
coohtermin
fusion
protein
present
foreign
antigen
nanoparticl
surfac
ebv
type
transmembran
protein
compos
amino
acid
includ
ectodomain
transmembran
domain
cytoplasm
tail
figur
analyz
differ
truncat
variant
abil
form
nanoparticl
found
smallest
variant
fail
express
ferritin
encapsulin
platform
suggest
instabl
variant
largest
variant
ectodomain
ferritin
express
howev
mixtur
assembl
misassembleddisassembl
speci
observ
exclud
use
construct
figur
two
truncat
variant
term
express
stabli
ferritin
encapsulin
without
disturb
selfassembl
nanoparticl
although
extens
posttransl
modifi
nand
olink
glycosyl
machiel
et
al
serafinicessi
et
al
shorter
truncat
elimin
mucinlik
domain
may
prevent
recognit
immun
system
figur
henc
select
studi
purifi
solubl
protein
nanoparticl
homogen
shown
size
exclus
chromatographi
figur
next
examin
antigen
display
nanoparticl
use
mab
mab
hoffman
et
al
recogn
site
potent
neutral
viru
wherea
mab
luka
et
al
nonneutr
antibodi
compet
ferritin
encapsulin
immunoprecipit
equival
irrelev
mab
okuno
et
al
figur
analog
solubl
ectodomain
nanoparticl
bound
howev
solubl
show
reduc
reactiv
mab
elisa
figur
suggest
conform
preserv
nanoparticl
solubl
alter
indic
solubl
form
differ
biochem
either
ectodomain
nanoparticl
although
overal
thermost
protein
similar
measur
differenti
scan
calorimetri
figur
assess
whether
nanoparticl
could
bind
cognat
ligand
test
bind
human
b
cell
flow
cytometri
expect
solubl
nanoparticl
bound
hi
b
cell
bind
depend
express
lo
b
cell
cell
show
weaker
bind
respect
figur
preincub
antibodi
diminish
bind
indic
interact
mediat
figur
electron
microscop
em
analysi
confirm
nanoparticl
form
monodispers
particl
globular
protrus
ferritin
encapsulin
nanoparticl
figur
cryoem
reconstruct
confirm
symmetri
ferritin
encapsulin
nanoparticl
figur
locat
protrus
ferritin
nanoparticl
correl
symmetri
form
dimer
howev
monomer
protrus
encapsulin
nanoparticl
well
separ
figur
although
predict
highli
glycosyl
dimer
interfac
observ
ferritin
cryoem
contain
hydrophob
patch
might
favor
form
dimer
expect
infer
expos
surfac
ferritin
readili
access
immun
recognit
figur
character
antibodi
respons
elicit
solubl
deriv
nanoparticl
mice
immun
mg
solubl
ectodomain
ferritin
encapsulin
presenc
sigma
adjuv
system
sa
week
first
dose
antibodi
bind
detect
mice
immun
ferritin
encapsulin
elisa
endpoint
titer
respect
titer
higher
found
mice
immun
ectodomain
figur
antibodi
also
measur
luciferas
immunoprecipit
system
lip
assay
shown
correl
well
ebv
neutral
activ
viru
neutral
assay
use
gfpreport
viru
sashihara
et
al
figur
second
dose
ferritin
encapsulin
substanti
increas
antibodi
titer
bind
dissoci
rate
antibodi
sera
also
improv
second
dose
measur
use
biolay
interferometri
figur
indic
antibodi
show
greater
affin
matur
bound
tightli
antibodi
elicit
first
dose
observ
vaccin
khurana
et
al
lee
et
al
second
inject
ectodomain
elicit
antibodi
titer
lower
mice
immun
ferritin
encapsulin
neutral
activ
sera
mice
immun
ectodomain
lower
sera
ferritin
encapsulin
immun
group
figur
discrep
also
observ
lip
assay
figur
immun
solubl
elicit
neglig
antibodi
respons
elisa
lip
viru
neutral
assay
indic
monomer
form
protein
much
less
immunogen
virusneutr
antibodi
induc
ferritin
alon
ferritin
mix
either
solubl
ectodomain
contrast
immun
ferritin
figur
data
document
physic
linkag
antigen
nanoparticl
requir
antigenspecif
immun
induct
show
ferritin
stimul
nonspecif
adjuv
respons
immun
lower
dose
mg
ferritin
induc
virtual
elisa
lip
neutral
antibodi
titer
mice
figur
next
assess
kinet
virusneutr
antibodi
immun
mice
two
month
second
dose
vaccin
week
neutral
antibodi
titer
mice
receiv
encapsulin
declin
peak
titer
remain
stabl
month
second
dose
without
immun
figur
neutral
antibodi
titer
mice
immun
ectodomain
slightli
increas
time
still
remain
low
level
figur
mice
immun
third
dose
week
titer
increas
ferritin
encapsulin
respect
ic
titer
respect
boost
titer
wane
rapidli
second
dose
remain
high
even
month
ic
titer
respect
figur
solubl
ectodomain
substanti
enhanc
neutral
antibodi
titer
three
immun
figur
observ
similar
titer
kinet
neutral
antibodi
lowerdos
mg
group
immun
ferritin
encapsulin
figur
importantli
crossreact
antibodi
autolog
ie
murin
ferritin
observ
even
three
immun
ferritin
mice
consist
previou
find
toler
homolog
ferritin
preserv
kanekiyo
et
al
figur
immunogen
nanoparticl
nonhuman
primat
evalu
vaccineinduc
immun
speci
close
relat
human
immun
cynomolgu
macaqu
macaca
fasciculari
monkey
given
mg
ectodomain
mg
either
ferritin
encapsulin
adjuv
sa
week
monkey
natur
infect
lymphocryptoviru
share
homolog
ebv
crossneutr
ebv
antibodi
found
monkey
prior
immun
ic
titer
figur
nevertheless
neutral
antibodi
titer
increas
two
dose
week
either
nanoparticl
titer
enhanc
baselin
third
dose
week
ferritin
respect
figur
neutral
titer
ectodomainimmun
anim
log
lower
although
overal
antibodi
bind
titer
similar
ferritin
encapsulinimmun
anim
figur
data
confirm
immunogen
nanoparticl
second
speci
indic
antibodi
product
enhanc
presenc
preexist
immun
test
efficaci
vaccineinduc
immun
mous
challeng
model
employ
recombin
viru
challeng
use
vaccinia
viru
express
ebv
construct
character
titrat
dose
viru
mice
establish
model
weight
loss
observ
result
infect
figur
report
parent
vaccinia
viru
chen
et
al
mice
challeng
month
third
immun
mice
immun
ectodomain
control
mice
one
except
lost
weight
within
day
requir
euthan
howev
four
five
ferritinimmun
mice
protect
show
milder
weight
loss
follow
rapid
recoveri
figur
p
mice
immun
ferritin
versu
ectodomain
observ
similar
find
mice
challeng
even
month
third
immun
figur
p
mice
immun
ferritin
versu
ectodomain
protect
observ
mice
immun
encapsulin
experi
figur
note
major
vaccinia
virion
would
envelop
plasma
membran
would
express
instead
envelop
would
deriv
endoplasm
reticulum
henc
antibodi
would
like
complet
neutral
incom
vaccinia
viru
particl
allow
incom
viru
infect
cell
least
one
round
replic
contrast
like
vaccinia
virusinfect
cell
express
surfac
prone
kill
antibodydepend
cell
cytotox
complementdepend
cytotox
cytotox
cell
think
one
mechan
mediat
viral
clearanc
vaccinia
challeng
model
observ
slightli
higher
neutral
activ
increas
bind
affin
antibodi
ferritinimmun
group
encapsulin
group
figur
differ
statist
signific
suggest
mechan
may
contribut
protect
defin
specif
antibodi
elicit
immunogen
use
surfac
plasmon
reson
immun
sera
collect
week
first
second
immun
analyz
elisa
lip
viru
neutral
assay
endpoint
bind
titer
left
lip
rel
light
unit
rlu
middl
neutral
ic
titer
right
determin
p
p
p
b
neutral
titer
mice
week
second
immun
ferritin
alon
ferritin
mix
ferritin
data
shown
boxandwhisk
plot
box
indic
lower
upper
quartil
line
median
whisker
span
minimum
maximum
data
point
individu
data
point
c
kinet
serum
neutral
titer
immun
ectodomain
nanoparticl
group
balbc
mice
n
immun
mg
ectodomain
ferritin
encapsulin
adjuv
week
immun
sera
collect
period
immun
serum
neutral
ic
titer
determin
plot
dot
repres
individu
mous
horizont
dot
line
repres
detect
limit
assay
see
also
figur
spr
base
antibodi
competit
assay
mclellan
figur
strikingli
half
total
antibodi
sera
elicit
either
ferritin
encapsulin
compet
mab
use
competitor
respect
wherea
antibodi
immun
sera
ectodomainimmun
anim
block
mab
figur
competit
demonstr
nanoparticl
predomin
target
recognit
howev
site
ectodomain
major
target
addit
differ
due
total
level
antibodi
sinc
elisa
endpoint
titer
differ
three
immun
group
second
dose
figur
interestingli
neglig
fraction
antibodi
immun
sera
compet
nonneutr
mab
ectodomain
ferritin
encapsulin
respect
although
epitop
equal
avail
access
immun
recognit
figur
confirm
function
relev
antibodi
immun
sera
design
ectodomain
mutant
abolish
bind
figur
one
mutant
extra
nlink
glycosyl
site
residu
anoth
mutant
two
extra
glycan
residu
report
critic
residu
bind
szakonyi
et
al
young
et
al
expectedli
glycan
mutat
reduc
bind
mab
glycan
complet
diminish
recognit
wherea
bind
mab
wildtyp
wt
remain
constant
figur
sera
mice
immun
ferrtin
encapsulin
preincub
wt
assess
viru
neutral
neutral
activ
deplet
antibodi
sera
absorb
excess
amount
wt
contrast
glycan
mutant
absorb
small
fraction
neutral
activ
indic
major
neutral
activ
target
site
block
mutant
figur
result
document
import
antibodi
viru
neutral
found
increas
serum
antibodi
bind
rel
fulllength
ectodomain
immun
nanoparticl
compar
immun
ectodomain
figur
although
overal
antibodi
bind
titer
similar
immun
group
figur
thu
document
preferenti
elicit
antibodi
immun
mice
monkey
natur
infect
ebv
induc
neutral
antibodi
respons
major
individu
although
titer
gener
modest
ic
sashihara
et
al
qualiti
immun
respons
often
key
determin
vaccineinduc
immun
independ
magnitud
noteworthi
solubl
ectodomain
effect
induc
neutral
antibodi
mice
unlik
nanoparticl
despit
fact
solubl
nanoparticl
form
similar
antigen
profil
observ
highlight
import
antigen
present
specif
conform
authent
function
domain
determin
qualiti
immun
respons
mclellan
immun
focus
nanoparticl
present
select
domain
enabl
elicit
antibodi
predominantli
provid
mechan
potent
neutral
sera
mode
neutral
target
receptorbind
site
rb
describ
virus
antibodi
bind
site
envelop
human
immunodefici
viru
potent
neutral
circul
viral
strain
regardless
sequenc
variabl
zhou
et
al
mab
whittl
et
al
other
neutral
influenza
virus
conserv
sialic
acidbind
site
viral
hemagglutinin
certain
mab
hepat
c
viru
krey
et
al
polioviru
chen
et
al
chen
et
al
herp
simplex
viru
lee
et
al
sever
acut
respiratori
syndrom
sar
coronaviru
van
den
brink
et
al
also
use
similar
mechan
neutral
virus
sinc
rb
must
function
conserv
engag
host
cell
receptor
one
vulner
target
viru
howev
isol
rbscontain
domain
rbd
often
weakli
immunogen
due
steric
hindranc
surround
glycan
hypervari
near
rb
impair
target
b
plasma
bind
antibodi
titer
immun
monkey
three
immun
symbol
repres
individu
monkey
horizont
dot
line
repres
detect
limit
assay
data
shown
boxandwhisk
plot
individu
data
point
immun
system
alter
conform
georgiev
et
al
joyc
et
al
julien
et
al
extens
glycosyl
ebv
thought
regul
immun
respons
glycoprotein
machiel
et
al
serafinicessi
et
al
one
principl
recombin
vaccin
design
improv
immunogen
nativ
protein
modifi
andor
alter
functionconfigur
otherwis
imposs
appli
certain
vaccin
platform
eg
kill
attenu
viru
truncat
coohtermin
residu
make
variant
almost
complet
remov
mucinlik
olink
glycanrich
domain
protein
howev
truncat
led
protein
misfold
andor
destabil
solubl
form
improv
immunogen
observ
display
ferritin
encapsulin
nanoparticl
suggest
conform
stabil
nanoparticl
without
remaind
domain
diamet
ferritin
encapsulin
particl
within
nm
therefor
like
traffic
lymph
node
similarli
would
taken
dendrit
cell
b
cell
macrophag
irvin
et
al
one
potenti
explan
differ
immunogen
orient
rb
rel
surfac
particl
mock
irrelev
nanoparticleimmun
mice
n
control
agematch
naiv
mice
n
see
also
figur
pack
densiti
paramet
would
quit
differ
ferritin
encapsulin
could
affect
access
angl
approach
immun
receptor
ferritin
rb
present
upright
space
within
distanc
would
allow
crosslink
b
cell
receptor
bcr
would
enhanc
signal
transduct
downstream
molecul
stimul
b
cell
activ
also
remain
possibl
dimer
seen
ferritin
effect
limit
solventexpos
surfac
nonrb
site
focus
immun
respons
rb
effici
recent
advanc
nanoparticl
technolog
accentu
benefit
symmetr
array
antigen
activ
b
cell
lowaffin
bcr
jardin
et
al
lingwood
et
al
improv
vaccineinduc
immun
technolog
allow
us
design
immunogen
elicit
immun
respons
target
otherwis
difficult
induc
nativ
protein
selfassembl
nanoparticlebas
ebv
vaccin
candid
display
receptorbind
portion
elicit
potent
neutral
activ
mice
nonhuman
primat
precis
target
site
vulner
viru
stimul
neutral
antibodi
respons
significantli
exceed
level
obtain
solubl
protein
anticip
synthet
approach
design
immunogen
offer
novel
opportun
creat
andor
redesign
vaccin
pathogen
difficult
induc
effect
immun
gene
encod
helicobact
pyloribullfrog
hybrid
ferritin
construct
fuse
residu
bullfrog
rana
catesbeiana
ferritin
lower
subunit
uniprot
mutat
abolish
potenti
nglycosyl
site
h
pylori
nonhem
ferritin
uniprot
residu
mutat
preserv
conserv
salt
bridg
found
human
bullfrog
ferritin
human
light
chain
bullfrog
lowersubunit
ferritin
bullfrog
ferritin
mutat
introduc
h
pylori
ferritin
abolish
potenti
nglycosyl
site
secret
encapsulin
construct
fuse
human
signal
termotoga
maritima
encapsulin
uniprot
residu
gene
encod
ebv
strain
uniprot
residu
synthes
fragment
correspond
ectodomain
residu
analog
region
use
crystal
structur
szakonyi
et
al
residu
residu
residu
amplifi
fragment
insert
bovin
prolactin
signal
bprl
hybrid
ferritin
fuse
end
encapsulin
sg
linker
give
rise
respect
solubl
ectodomain
construct
fuse
correspond
fragment
bprl
coohtermin
hexahistidin
tag
mutant
made
introduc
nglycosyl
site
sprbase
crosscompetit
assay
immun
sera
mab
bind
immun
sera
second
immun
mabsatur
measur
biacor
curv
repres
individu
serum
data
normal
curv
shown
fraction
respons
crosscompetit
immun
sera
left
right
shown
differ
immun
group
b
specif
antibodi
immun
sera
percent
inhibit
serum
antibodi
bind
calcul
c
gener
ebv
mutant
domain
ii
shown
blue
sky
blue
respect
attach
glycan
shown
yellow
sphere
residu
shown
red
infer
indic
pdb
left
bind
wt
mutant
mab
measur
elisa
right
symbol
repres
mean
sd
serum
neutral
titer
determin
absenc
close
circl
presenc
wt
open
circl
open
squar
protein
e
preferenti
elicit
antibodi
respons
mice
monkey
serum
antibodi
respons
either
wt
measur
second
immun
indic
immunogen
endpoint
elisa
antibodi
titer
wt
determin
ratio
titer
calcul
wt
data
b
e
shown
boxandwhisk
plot
individu
data
point
p
p
p
p
see
also
figur
gene
clone
cmvr
vrc
mammalian
express
vector
protein
product
express
vector
transient
transfect
freestyl
cell
use
expifectamin
transfect
reagent
respect
life
technolog
nanoparticl
purifi
affin
chromatographi
use
galanthu
nivali
agglutinin
resin
ey
laboratori
follow
size
exclus
chromatographi
hiprep
sephacryl
hr
column
ge
healthcar
solubl
protein
purifi
use
ni
sepharos
excel
resin
ge
healthcar
follow
size
exclus
chromatographi
superdex
gl
ge
healthcar
neg
stain
electron
microscopi
em
sampl
mg
ml
adsorb
freshli
glowdischarg
carbonco
grid
stain
ammonium
molybd
imag
record
fei
microscop
eagl
ccd
camera
cryoem
sampl
mg
ml
ml
appli
holey
grid
quantifoil
fastfrozen
liquid
ethan
describ
previous
meng
et
al
cryoem
imag
ferritin
encapsulin
acquir
fei
titan
krio
oper
kev
feg
microscop
oper
kev
respect
imag
process
threedimension
reconstruct
perform
use
particl
eman
suit
program
baker
et
al
final
reconstruct
comput
lowpass
filter
resolut
fit
model
made
use
emfit
program
rossmann
et
al
anim
experi
carri
accord
feder
regul
nih
guidelin
approv
institut
anim
care
use
committe
eightto
old
femal
balbc
mice
charl
river
laboratori
immun
n
intramuscularli
mg
purifi
protein
ml
vv
mixtur
sa
adjuv
sigma
pb
week
nonhuman
primat
studi
eight
cynomolgu
macaqu
macaca
fasciculari
immun
mg
ectodomain
mg
ferritin
encapsulin
sa
adjuv
intramuscularli
week
neutral
ebv
b
cell
describ
previous
sashihara
et
al
briefli
immun
sera
serial
dilut
incub
report
viru
gfpreport
ebv
hr
protein
competit
neutral
sera
preincub
either
solubl
wt
mutant
protein
mg
ml
min
mixtur
ad
raji
cell
incub
day
cell
fix
analyz
accuri
flow
cytomet
bd
bioscienc
neutral
antibodi
titer
express
concentr
serum
antibodi
need
inhibit
viral
entri
ic
fulllength
ebv
clone
plasmid
encod
vaccinia
viru
vv
requir
plaqu
format
blasco
moss
cell
infect
vv
subsequ
transfect
contain
ebv
recombin
viru
rescu
purifi
plaqu
purif
challeng
stock
purifi
cushion
sucros
ultracentrifug
g
min
titrat
cell
immun
mice
challeng
intranas
pfu
viru
ml
per
nostril
mice
monitor
euthan
lost
prechalleng
weight
suffer
symptom
surfac
plasmon
resonancebas
antibodi
competit
solubl
wt
protein
immobil
sensor
chip
ge
healthcar
fifti
microlit
mg
ml
mab
flow
chip
ml
min
inject
ml
serum
sampl
dilut
ml
ml
biacor
instrument
ge
healthcar
chip
regener
use
mgcl
run
analysi
p
valu
gener
oneway
anova
use
prism
program
graphpad
softwar
unless
report
otherwis
structur
render
protein
gener
use
ucsf
chimera
packag
version
http
wwwcglucsfeduchimera
ucsf
chimera
develop
resourc
biocomput
visual
informat
univers
california
san
francisco
support
nigm
